NASDAQ:LMAT

LeMaitre Vascular Stock Forecast, Price & News

$58.15
+0.67 (+1.17 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$57.91
$59.37
50-Day Range
$53.84
$60.45
52-Week Range
$31.21
$64.50
Volume126,695 shs
Average Volume128,991 shs
Market Capitalization$1.26 billion
P/E Ratio41.83
Dividend Yield0.77%
Beta1.32
30 days | 90 days | 365 days | Advanced Chart
Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.


LeMaitre Vascular logo

About LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.53 out of 5 stars

Medical Sector

235th out of 1,352 stocks

Surgical & Medical Instruments Industry

28th out of 123 stocks

Analyst Opinion: 2.3Community Rank: 4.9Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

Is LeMaitre Vascular a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LeMaitre Vascular stock.
View analyst ratings for LeMaitre Vascular
or view top-rated stocks.

What stocks does MarketBeat like better than LeMaitre Vascular?

Wall Street analysts have given LeMaitre Vascular a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but LeMaitre Vascular wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting LeMaitre Vascular?

LeMaitre Vascular saw a drop in short interest in July. As of July 30th, there was short interest totaling 1,050,000 shares, a drop of 18.0% from the July 15th total of 1,280,000 shares. Based on an average trading volume of 146,000 shares, the days-to-cover ratio is presently 7.2 days. Currently, 5.6% of the shares of the company are sold short.
View LeMaitre Vascular's Short Interest
.

When is LeMaitre Vascular's next earnings date?

LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for LeMaitre Vascular
.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings results on Thursday, July, 29th. The medical instruments supplier reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. The medical instruments supplier earned $40.67 million during the quarter, compared to the consensus estimate of $40.70 million. LeMaitre Vascular had a net margin of 19.12% and a trailing twelve-month return on equity of 16.51%.
View LeMaitre Vascular's earnings history
.

How has LeMaitre Vascular's stock been impacted by Coronavirus?

LeMaitre Vascular's stock was trading at $26.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LMAT shares have increased by 122.8% and is now trading at $58.15.
View which stocks have been most impacted by COVID-19
.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Thursday, July 29th. Shareholders of record on Thursday, August 26th will be paid a dividend of $0.11 per share on Thursday, September 9th. This represents a $0.44 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Wednesday, August 25th.
View LeMaitre Vascular's dividend history
.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular pays an annual dividend of $0.44 per share and currently has a dividend yield of 0.77%. LeMaitre Vascular does not yet have a strong track record of dividend growth. The dividend payout ratio of LeMaitre Vascular is 42.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 29.14% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.
View LeMaitre Vascular's dividend history.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of $1.300-$1.400 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.260. The company issued revenue guidance of $154.10 million-$158.10 million, compared to the consensus revenue estimate of $152.09 million.

What price target have analysts set for LMAT?

5 Wall Street analysts have issued 12-month price targets for LeMaitre Vascular's stock. Their forecasts range from $58.00 to $70.00. On average, they anticipate LeMaitre Vascular's stock price to reach $64.25 in the next year. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for LeMaitre Vascular
or view top-rated stocks among Wall Street analysts.

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the following people:
  • George W. LeMaitre, Chairman & Chief Executive Officer
  • David B. Roberts, President & Director
  • Trent G. Kamke, Senior Vice President-Operations (LinkedIn Profile)
  • Joseph P. Pellegrino, CFO, Secretary, Treasurer & Director
  • Jonathan W. Ngau, Vice President-Information Technology

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular CEO George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among LeMaitre Vascular's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of LeMaitre Vascular's key competitors?

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include (CGC), AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), The Boeing (BA) and salesforce.com (CRM).

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.28%), Conestoga Capital Advisors LLC (8.86%), Vanguard Group Inc. (5.30%), Copeland Capital Management LLC (4.47%), Geneva Capital Management LLC (4.17%) and State Street Corp (3.21%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends for LeMaitre Vascular
.

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Tygh Capital Management Inc., Kennedy Capital Management Inc., Conestoga Capital Advisors LLC, and Russell Investments Group Ltd.. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski, and Trent G Kamke.
View insider buying and selling activity for LeMaitre Vascular
or view top insider-selling stocks.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was bought by a variety of institutional investors in the last quarter, including Amundi, ProShare Advisors LLC, Goldman Sachs Group Inc., Copeland Capital Management LLC, Vanguard Group Inc., Parametric Portfolio Associates LLC, Charles Schwab Investment Management Inc., and Jackson Creek Investment Advisors LLC.
View insider buying and selling activity for LeMaitre Vascular
or or view top insider-buying stocks.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $58.15.

How much money does LeMaitre Vascular make?

LeMaitre Vascular has a market capitalization of $1.26 billion and generates $129.37 million in revenue each year. The medical instruments supplier earns $21.22 million in net income (profit) each year or $1.04 on an earnings per share basis.

How many employees does LeMaitre Vascular have?

LeMaitre Vascular employs 395 workers across the globe.

Does LeMaitre Vascular have any subsidiaries?

The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.

When was LeMaitre Vascular founded?

LeMaitre Vascular was founded in 1983.

What is LeMaitre Vascular's official website?

The official website for LeMaitre Vascular is www.lemaitre.com.

Where are LeMaitre Vascular's headquarters?

LeMaitre Vascular is headquartered at 63 SECOND AVENUE, BURLINGTON MA, 01803.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at (781) 221-2266.


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.